PEGS 2026 x KACTUS

By Hannah Flaherty

May 5, 2026

KACTUS is excited to join the 22nd Annual Protein Engineering Summit (PEGS Boston), taking place May 11 to 15, 2026 in Boston, Massachusetts. As one of the industry’s premier events for biologics and protein engineering, PEGS convenes global leaders in antibody discovery, protein engineering, immunotherapy, bispecifics, cell therapy, and AI-enabled therapeutic development.

What is the Protein Engineering & Cell Therapy Summit?

The Protein Engineering Summit (PEGS) is one of the world’s leading conferences for biologics and protein engineering. Bringing together researchers, biopharma innovators, and technology developers, PEGS serves as a hub for the latest advancements in antibody engineering, immunotherapy, protein therapeutics, oncology, cell therapy, and machine learning-driven drug discovery. Its scientific depth and collaborative environment make it a cornerstone event for therapeutic innovation.

Event Overview 

Venue: Omni Boston Hotel at the Seaport, Boston, MA

Dates: May 11 to 15, 2026

  • Conference Day 1: Monday, May 11 7:30 AM to 7:15 PM

    •  Exhibit Hall Open: 5:55 PM to 7:15 PM

  • Conference Day 2: Tuesday, May 12 7:30 AM to 6:00 PM

    • Exhibit Hall Open: 10:30 AM to 4:40 PM

  • Conference Day 3: Wednesday, May 13  8:25 AM to 7:20 PM

    • Exhibit Hall Open: 9:15 AM to 7:20 PM

  • Conference Day 4: Thursday, May 14 7:30 AM to 5:30 PM

    •  Exhibit Hall Open: 10:30 AM to 1:55 PM

  • Conference Day 5: Friday, May 15
    7:30 AM to 5:30 PM

Booth #411

Featured Talk

Luncheon Presentation: Precision CD3 Targeting: Next-Generation Functional Lead Discovery with Advanced VLP and Nanodisc Platforms

  • Speaker: Anil Kumar, Business Development Manager, DACH Region, KACTUS

  • Date & Time: Wednesday, May 13, 2026 at 11:40 AM

Presentation Overview:
Antibody discovery against CD3 is often limited by non-native protein formats that yield non-functional binders. This presentation highlights KACTUS precision CD3 tools, including engineered heterodimers, TCR-CD3 VLPs, and nanodiscs, designed to better mimic native structure and signaling. These advanced platforms support improved immunization, screening, and characterization for more reliable identification of functional therapeutic leads.

Posters

A068: Recombinant Kallikrein (KLK) Family Proteins

A069: The Native Edge: KACTUS CD3 VLPs and Nanodiscs for Precision T-Cell Therapy and Discovery

B060: Transforming Tumor Research: Engineering MHCs as Versatile Reagents

Event Schedule 

PEGS Boston 2026 brings together the world’s leading experts in protein engineering, antibody discovery, immunotherapy, and next-generation therapeutic development for a week of cutting-edge scientific programming. Attendees can expect technical sessions, poster presentations, dedicated exhibit hall networking, and industry receptions designed to foster collaboration across the biologics landscape. Explore the key exhibit hall and networking highlights below.

Monday, May 11

  • Conference Sessions: 7:30 AM to 7:15 PM

  • Exhibit Hall & Poster Viewing: 5:55 PM to 7:15 PM

  • Welcome Reception: 5:55 PM to 7:15 PM

Tuesday, May 12

  • Conference Sessions: 7:30 AM to 6:00 PM

  • Exhibit Hall & Poster Viewing: 10:30 AM to 4:40 PM

  • Grand Opening Coffee Break: 10:35 AM to 11:15 AM

  • Dessert Break: 1:50 PM to 2:20 PM

  • Refreshment Break: 4:00 PM to 4:40 PM

Wednesday, May 13

  • Conference Sessions: 8:25 AM to 7:20 PM

  • Exhibit Hall & Poster Viewing: 9:15 AM to 7:20 PM

  • Coffee Break: 9:15 AM to 10:00 AM

  • Ice Cream Break: 3:40 PM to 4:20 PM

  • Networking Reception: 6:20 PM to 7:20 PM

Thursday, May 14

  • Conference Sessions: 7:30 AM to 5:30 PM

  • Exhibit Hall & Poster Viewing: 10:30 AM to 1:55 PM

  • Coffee Break: 10:50 AM to 11:35 AM

  • Luncheon: 12:30 PM to 2:05 PM (Last Chance for Poster Viewing)

Friday, May 15

  • Conference Sessions: 7:30 AM to 5:30 PM

About KACTUS

KACTUS specializes in the development and production of high-quality, bioactive recombinant proteins and enzymes that support innovation across antibody drug discovery, immunotherapy, gene therapy, and mRNA therapeutics. With a catalog of over 2,500 recombinant proteins spanning diverse targets, species, tags, and formats, we are committed to meeting the evolving needs of scientists in translational research. Our focus on rigorous quality control and reliable supply ensures the consistency and performance that today’s therapeutic development demands.

Featured Products 

MHC Monomers & Tetramers

Transmembrane Proteins 

CD3 Proteins and Nanodiscs